LifeScience Clinical & Diagnostic
Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial
Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...
September 04, 2026 | News
Norroy Bioscience Secures China Clearance for Phase III Trial of PSMA-Targeted Radiopharmaceutical
NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regu...
September 04, 2026 | News
Alteogen, Novartis Ink Up to $3.2B Deal for Subcutaneous Biologics Using ALT-B4
Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreem...
September 04, 2026 | News
EpiVax Adds AI-Enabled Enhancements to ISPRI Immunogenicity Risk Platform
EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the ...
September 04, 2026 | News
Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
September 04, 2026 | News
IDT and Ansa Expand Global Access to Complex DNA Synthesis Through Integrated Ordering
Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options Global adoption growing with more than 400...
September 03, 2026 | News
Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis
Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...
September 03, 2026 | News
Singapore Becomes First ASEAN Market to Subsidise Vutrisiran for ATTR Amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong ...
September 02, 2026 | News
Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies
Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, an...
September 02, 2026 | News
Astellas Reaches US Government Agreement to Lower Medicaid Drug Prices, Strengthen Medicine Supply Chain
Agreement supports commitment to patient access, affordability and innovation – Astellas Pharma Inc. announced that it has reached an agreemen...
September 02, 2026 | News
ReviR Therapeutics’ RTX-117 Secures FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth Disease
Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approv...
August 28, 2026 | News
US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...
August 27, 2026 | News
Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...
August 26, 2026 | News
Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension
Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the f...
August 24, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
